Cytotoxic effects of hydroxy coumarin derivations to neuroblastoma N2a cells

Document Type : Research Paper


1 Department of Biology, Faculty of Science, Arak University, Arak, Iran;Department of laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Biochimestry, Payame Noor University, Mashhad, Iran

4 Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad 917794-8564, Iran.



Neuroblastoma is one of the nervous system cancers, which approximately consists of 9% of childhood cancers. In this study, we evaluated the toxic effects of prenyl hydroxy coumarin derivatives on apoptosis of the neuroblastoma cell line N2A. N2a cells were cultured in DMEM medium, then the effects of different concentrations (0.75–200 μg/mL) of prenyl hydroxy coumarin derivatives during 24, 48, and 72 h were studied. Cell viability was quantified by MTT assay; apoptotic cells were determined using PI staining of DNA fragmentation by Flow cytometry (sub-G1 peak). The toxic effect of 3- farnesyl oxi coumarin in the N2A cell starts at 6.25 μg/ml and increases relatively depending on rising in concentration and time. The toxicity and apoptosis in 3- farnesyl and 6- farnesyl oxi coumarin is more than 3- Geranyl and 6-Geranyl oxi coumarin. Prenyl hydroxy coumarin induces peak sub-G1in flow cytometry compared to the control group, indicating prenyl hydroxy coumarin-induced toxicity, which is involved in apoptotic cell death. Different concentration of hydroxy coumarin derivatives (0.75-200) µg/mL in lymphocytes, did not induce any anti-proliferative effect in 24 h.
In conclusion, prenyl hydroxy coumarin derivatives induce apoptotic effects in the N2A cell line. Thus prenyl hydroxy coumarin derivatives sound to be chemotherapeutic agents for the neuroblastoma cancer cells.


 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA.Cancer J. Clin. (2018) 68 (6): 394-424.
[2] Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L and Fleming T. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. J.A.M.A. Oncol. (2015) 3(4): 524-548.
[3] Kumar N, Bhatnagar A and Dudhe R. Synthesis of 3-(4, 5-dihydro-1-phenyl-5-substituted phenyl-1H-pyrazol-3-yl)-2H-chromen-2-one derivatives and evaluation of their anticancer activity. Arab. J. Chem. (2017) S2443-S2452.
[4] Palethorpe HM, Smith E, Tomita Y, Nakhjavani M, Yool AJ, Price TJ, Young JP, Townsend AR and Hardingham JE. Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. Molecules (2019) 24 (19): 3539.
[5] Nakhjavani M, Hardingham JE, Palethorpe HM, Tomita Y, Smith E, Price TJ and Townsend AR. Ginsenoside Rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines (2019) 6 (1): 17.
[6] Nakhjavani M, Palethorpe HM, Tomita Y, Smith E, Price TJ, Yool AJ, Pei JV, Townsend AR and Hardingham JE.Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models. Pharmaceuticals (2019) 12 (3): 117.
[7] Louis CU and Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu. Rev. Med. (2015) 66: 49-63.
[8] Gurney JG, Ross JA, Wall DA and Bleyer WA, Severson RK and Robison LL. Infant cancer in the US: histology-specific incidence and trends, 1973 to 1992. J. Pediatr. Hematol. Oncol. (1997) 19 (5): 428-432.
[9] Pizzo PA and Poplack DG. Principles and practice of pediatric oncology: Lippincott Williams & Wilkins: USA (2015).
[10] Tolbert VP and Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res.(2018) 1-15.
[11] Group UCSW. United States cancer statistics: 1999–2006 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. http://cdc. gov/uscs (2010).
[12] Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B and Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. CELL PROLIFERAT. (2012) 45(6): 487-498.
[13] Bai L and Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu. Rev. Med. (2014) 139-155.
[14] Xu X, Zhang Y, Qu D, Jiang T and Li S. Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. J. Exp. Clin. Cancer. Res. (2011) 30 (1): 33.
[15] Zhou X, Wang X-B, Wang T and Kong L-Y. Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg. Med. Chem. (2008) 16(17): 8011-8021.
[16] Zahir NV, Nakhjavani M, Hajian P, Shirazi FH and Mirzaei H. Evaluation of Silibinin effects on the Viability of HepG2 (Human hepatocellular liver carcinoma) and HUVEC (Human Umbilical Vein Endothelial) cell lines. Iran J. Pharm. Res. (2018) 17(1): 261
[17] Vakili N, Nakhjavani M, Mirzayi H and Shirazi FH. Studying silibinin effect on human endothelial and hepatocarcinoma cell lines. Res. Pharm. Sci.  (2012) 7(5): 174.
[18] Lacy A and O'kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr. Pharm. Des. (2004) 10(30): 3797-3811.
[19] Jain P and Joshi H. Coumarin: Chemical and pharmacological profile. J. Appl. Pharm. Sci. (2012): 236-240.
[20] Cooke D, Fitzpatrick B, O’Kennedy R, Mc Cormack T and Egan D. Coumarin Biochemical Profile and Recent Developments. J.WS. (1997).
[21] Cooke D. Recent Advances on Coumarin and its Synthetic Derivatives. D.C.U. (1999) 12: 125-139.
[22] Lee S-J, Lee U-S, Kim W-J and Moon S-K. Inhibitory effect of esculetin on migration, invasion and matrix metalloproteinase-9 expression in TNF-α-induced vascular smooth muscle cells. MOL. MED. REP. (2011) 4 (2): 337-341.
[23] Nitiema LW, Savadogo A, Simpore J, Dianou D and Traore AS. In vitro antimicrobial activity of some phenolic compounds (coumarin and quercetin) against gastroenteritis bacterial strains. Int. J. Microbiol. Res. (2012) 3 (3): 183-187.
[24] Ebbinghaus S, Mahler J and Marshall M. Novel Coumarin activity on albino rats and shows anti-coagulant and anti-oxidant activity. J.W.S. (1997) 45: 195-209.
[25] Huang XY, Shan ZJ, Zhai HL, Su L and Zhang XY. Study on the anticancer activity of coumarin derivatives by molecular modeling. Chem. Biol. Drug. Des. (2011);78(4): 651-658.
[26] Yeh JY, Coumar MS, Horng JT, Shiao HY, Kuo FM, Lee HL, Chen IC, Chang CW, Tang WF, Tseng SN and Chen CJ. Anti-Influenza Drug Discovery: Structure− Activity Relationship and Mechanistic Insight into Novel Angelicin Derivatives. J. Med. Chem. (2010);53(4): 1519-1533.
[27] Asif M. Pharmacologically potentials of different substituted coumarin derivatives. Chem. Int. (2015);1(1): 1-11.
[28] Iranshahi M, Arfa P, Ramezani M, Jaafari MR, Sadeghian H, Bassarello C, Piacente S and Pizza C. Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes. Phytochemistry (2007);68(4): 554-561.
[29] Russo P, Cimoli G, Valenti M, Sessa FD, Parodi S and Pommier Y. Induction of DNA double-strand breaks by 8-methoxycaffeine: cell cycle dependence and comparison with topoisomerase II inhibitors. Carcinogenesis (1994);15(11): 2491-2496.
[30] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. IMMUNOL. METHODS (1983);65(1): 55-63.
[31] Zhuang C, Itoh H, Mizuno T and Ito H. Antitumor active fucoidan from the brown seaweed, umitoranoo (Sargassum thunbergii). Biosci. Biotechnol. Biochem. (1995);59(4): 563-567.
[32] Tayarani-Najaran Z, Mousavi SH, Vahdati-Mashhadian N, Emami SA and Parsaee H. Scutellaria litwinowii induces apoptosis through both extrinsic and intrinsic apoptotic pathways in human promyelocytic leukemia cellsNutr. Cancer (2012) 64(1): 80-88
[33] Singh RK, Lange TS, Kim KK and Brard L. A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells. Invest. New Drugs (2011);29(1): 63-72.
[34] Musa MA, Joseph MY, Latinwo LM, Badisa V and Cooperwood JS. In Vitro Evaluation of 3-Arylcoumarin Derivatives in A549 Cell Line. Anticancer Res. (2015);35(2): 653-659.
[35] Khaghanzadeh N, Mojtahedi Z, Ramezani M, Erfani N and Ghaderi A. Umbelliprenin is cytotoxic against QU-DB large cell lung cancer cell line but anti-proliferative against A549 adenocarcinoma cells. DARU (2012);20(1): 69.
[36] Wang J, Lu M, Dai H, Zhang S, Wang H and Wei N. Esculetin, a coumarin derivative, exerts in vitro and in vivo antiproliferative activity against hepatocellular carcinoma by initiating a mitochondrial-dependent apoptosis pathway. Braz. J. Med. Biol. Res. (2015);48(3): 245-253.
[37] Zhang W, Li Z, Zhou M, Wu F, Hou X, Luo H, Liu H, Han X, Yan G, Ding Z and Li R. Synthesis and biological evaluation of 4-(1, 2, 3-triazol-1-yl) coumarin derivatives as potential antitumor agents. Bioorg. Med. Chem. Lett. (2014);24(3): 799-807.
[38] Hoult J and Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol. (1996);27(4): 713-722.
[39] Klenkar J and Molnar M. Natural and synthetic coumarins as potential anticancer agents. J. Chem. Pharm. Res. (2015);7(7): 1223-1238.
[40] Jun M, Bacay AF, Moyer J, Webb A and Carrico-Moniz D. Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents. Bioorg. Med. Chem. Lett. (2014);24(19): 4654-4658.
[41] Bourgaud F, Hehn A, Larbat R, Doerper S, Gontier E, Kellner S and Matern U. Biosynthesis of coumarins in plants: a major pathway still to be unravelled for cytochrome P450 enzymes. Phytochem Rev.(2006);5(2-3): 293-308.
[42] Farooq S. 555 medicinal plants. Field and laboratory manual (identification with its phytochemical and in vitro studies data): International Book Distributors; India (2005).
[43] Rosselli S, Maggio AM, Faraone N, Spadaro V, Morris-Natschke SL, Bastow KF, Lee KH and Bruno M. The cytotoxic properties of natural coumarins isolated from roots of Ferulago campestris (Apiaceae) and of synthetic ester derivatives of aegelinol. Nat. Prod. Commun. (2009) 4(12): 1701-1706.
[44] Crombie L, Games D and McCormick A. Isolation and structure of mammea A/BA, A/AB and A/BB: A group of 4-aryl-coumarin extractives of mammea americana L. Tetrahedron Lett. (1966)7(2): 145-149.
[45] Poole SK and Poole CF. Thin-layer chromatographic method for the determination of the principal polar aromatic flavour compounds of the cinnamons of commerce. A.N.A.L. (1994);119(1): 113-120.
[46] Soltani F, Mosaffa F, Iranshahi M, Karimi G, Malekaneh M, Haghighi F and Behravan J. Auraptene from Ferula szowitsiana protects human peripheral lymphocytes against oxidative stress. Phytother Res. (2010) 24(1): 85-89.
[47] Lariche N, Mesbah L, Benguedouar L and Zellagui A. Ferulenol, a Sesquiterpene Coumarin, Induce Apoptosis via Mitochondrial Dysregulation in Lung Cancer Induced by Benzo [a] pyrene: Involvement of Bcl2 Protein.  Anticancer Agents. Med. Chem. (2017): 1357-1362.
[48] Salla S, Sunkara R, Walker LT and Verghese M. Antioxidant and Apoptotic Activity of Papaya Peel Extracts in HepG2 Cells. Food Nutr. Sci. (2016) 7 (6): 485.
[49] Egan D, James P, Cooke D and O'Kennedy R. Studies on the cytostatic and cytotoxic effects and mode of action of 8-nitro-7-hydroxycoumarin. Cancer Lett. (1997) 118 (2): 201-211.
[50] Brohem CA, Sawada TC, Massaro RR, Almeida RL, Rivelli DP, Ropke CD, Da Silva VV, De Lima TM, Curi R, Barros SB, Maria-Engler SS. Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines. Toxicol. In Vitro (2009) 23(1): 111-119.
[51] Borhani N, Manoochehri M, Gargari SS, Novin MG, Mansouri A and Omrani MD. Decreased expression of proapoptotic genes caspase-8-and BCL2-associated agonist of cell death (BAD) in ovarian cancer. Clin. Ovarian Cancer Other Gynecol. cancer (2014): 18-23.